tbuckley/cabot-search huggingface dataset:
OA 09.03 TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI
Authors: M. Ahn, J. Han, L. Sequist, B.C. Cho, J.S. Lee, S. Kim, W. Su, C. Tsai, J.C. Yang, H. Yu, L. Horn, K. Lee, V. Haddad, M. Frigault, G. Ahmed, L. Yang, D. Ghiorghiu, G. Oxnard
Journal: Journal of Thoracic Oncology (2017)
P2.01-034 Phase I/II Trial of Weekly Nab-Paclitaxel as 2nd or 3rd Line Treatment in NSCLC Without Driver Mutations. (OLCSG1303)
Authors: K. Kudo, S. Kuyama, D. Harada, T. Kozuki, A. Bessho, K. Hotta, H. Yoshioka, K. Gemba, N. Takigawa, I. Oze, K. Kiura
Journal: Journal of Thoracic Oncology (2017)
OA 10.06 Longitudinal Mutation Monitoring in Plasma by Deep Sequencing as a Potential Predictor of Disease Progression in NSCLC
Authors: J. Jiang, H. Adams, M. Lange, S. Siemann, M. Feldkamp, S. Schulze, S. Froehler, S. Yaung, L. Yao, A. Balasubramanyam, N. Tikoo, H.J. Achenbach, R. Krügel, J. Palma, A. Rosenthal
Journal: Journal of Thoracic Oncology (2017)
PUB058 Is Efficacy Result in Phase 2 Trial Replicated in Phase 3 Trial in Advanced NSCLC: A Meta-Analysis
Authors: R. Shibaki, H. Akamatsu, K. Mori, S. Teraoka, K. Kanai, A. Hayata, N. Tokudome, K. Akamatsu, Y. Koh, H. Ueda, M. Nakanishi, N. Yamamoto
Journal: Journal of Thoracic Oncology (2017)
Potential role of IgM-enriched immunoglobulin as adjuvant treatment for invasive meningococcal disease
Authors: Carlo Tascini, Fiorentino Fraganza, Francesca Salani, Emanuela Sozio, Marco Rossi, Francesco Sbrana, Novella Carannante, Maria Daniela Chiesa, Andrea Ripoli, Giacomo Bertolino, Massimo Di Pietro, Alessandro Bartoloni, Francesco Menichetti
Journal: Intensive Care Medicine (2017)
Abstract 15950: Does Left Atrial Scar Predict Atrial Fibrillation in Elderly Patients?
Authors: Sanghamitra Mohanty, Chintan Trivedi, Carola Gianni, John David Burkhardt, Javier Sanchez, Patrick Hranitzky, G. Joseph Gallinghouse, Amin Al-Ahmad, Rodney Horton, Richard Hongo, Sakis Themistoclakis, Antonio Dello Russo, Claudio Tondo, Luigi Di Biase, Andrea Natale
Journal: Circulation (2016)

Background:  Left atrial (LA) scar could provide a substrate for atrial fibrillation (AF). Scar can be the manifestation of an existing aging-related structural remodeling, especially in older patients. However, not all elderly patients with LA scar develop AF.   Purpose:  We examined the clinical characteristics and scar prevalence in patients aged ≥ 75 years with and without AF to understand the relationship between scar and AF.   Method:  Five hundred seventy one patients undergoing radio-frequency catheter ablation for AF or supraventricular tachycardia (SVT) were included in this prospective analysis and classified into 2 groups; group 1: patients with AF (n=308) and group 2: patients with diagnosis of SVT (n=263). Left atrial (LA) scarring was determined by three-Dimensional (3D) voltage mapping.   Results:  Left atrial scar was detected in 172 (56%) patients in group 1 and 134 (51%) in group 2 (p=0.24). After adjusting for age and gender in multivariable logistic model, diagnosis of AF or SVT did not show any association with the incidence of scar (p=0.22). Based on the 3D mapping, 52(30%) patients had mild, 88(51%) had moderate and 32(19%) had severe scar in group 1 and mild 50(37%), moderate 67(50%), and severe in 17(13%) in group 2 (p=0.248). No difference in age, gender and distribution of comorbidities were observed between groups (Table 1).   Conclusion:  Our results indicate that scar facilitates AF in predisposed subjects only and AF susceptibility may be determined by a combination of comorbidities and genetic predisposition.
NCOG-06. N107C/CEC.3 (ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY/CANADIAN CANCER TRIALS GROUP): PHASE III TRIAL OF POST-OPERATIVE RADIOSURGERY COMPARED WITH WHOLE BRAIN RADIOTHERAPY FOR RESECTED METASTATIC BRAIN DISEASE: COGNITIVE FUNCTION OF LONG-TERM SURVIVORS
Authors: David Roberge, Karla Ballman, Jane Cerhan, S Keith Anderson, Xiomara Carrero, Anthony Whitton, Jeffrey N Greenspoon, Ian Parney, Nadia N Laack, Jonathan Ashman, Jean-Paul Bahary, Constantinos Hadjipanayis, James Urbanic, Fred Barker, Elana Farace, Deepak Khuntia, Yolanda Garces, Caterina Giannini, Jan C Buckner, Evanthia Galanis, Paul Brown
Journal: Neuro-Oncology (2017)

It has been our recent finding that, when substituted for whole brain radiotherapy (WBRT) as an adjuvant to resection of a brain metastasis, radiosurgery (SRS) results in improved cognitive outcomes and equivalent overall survival — this despite inferior long-term local control. A subgroup of patients will be long-term survivors following local treatment of their brain metastases. Here we report an unplanned analysis of the outcomes of patients surviving more than 12 months following surgery. Patients were randomized to either radiosurgery or WBRT after resection of a brain metastasis. The primary endpoints were neurocognitive progression and overall survival. In this report, cognitive deterioration is defined as a 1-SD drop in at least 1 cognitive test. This study is registered with ClinicalTrials.gov, number NCT01372774. Between July 2011 and December 2015, 194 patients were enrolled with a median follow-up of 11·1 months (maximum 49·0 months). Baseline characteristics were well-balanced between study arms. At 12 months, there were 47 patients alive in the SRS arm and 42 in the WBRT arm; at 24 months, there were 14 and 22 survivors in the SRS and WBRT arms, respectively. At 12 months the intracranial control was 72% in the WBRT arm and 34% in the SRS arm (p<0.0001). At 12 months, 60% of SRS patients tested had neurocognitive progression vs. 91% of WBRT-treated patients (p<0.02). At 24 months, 40% of SRS patients tested had neurocognitive progression vs. 75% of WBRT-treated patients (p=0.2). At 24 months, no radiosurgery patient had a significant decline in immediate recall (HVLT-R) vs. 50% of WBRT patients (p=0.015). Decline in cognitive function occurs early after treatment of brain metastases and remains relatively stable over time. Despite inferior intracranial control, the cognitive advantage of SRS is preserved in long-term survivors. SUPPORT: U10CA180821, U10CA180882, U10CA180868, UG1CA189823.
Faster Evolving Primate Genes Are More Likely to Duplicate
Authors: Áine N O’Toole, Laurence D Hurst, Aoife McLysaght
Journal: Molecular Biology and Evolution (2017)

An attractive and long-standing hypothesis regarding the evolution of genes after duplication posits that the duplication event creates new evolutionary possibilities by releasing a copy of the gene from constraint. Apparent support was found in numerous analyses, particularly, the observation of higher rates of evolution in duplicated as compared with singleton genes. Could it, instead, be that more duplicable genes (owing to mutation, fixation, or retention biases) are intrinsically faster evolving? To uncouple the measurement of rates of evolution from the determination of duplicate or singleton status, we measure the rates of evolution in singleton genes in outgroup primate lineages but classify these genes as to whether they have duplicated or not in a crown group of great apes. We find that rates of evolution are higher in duplicable genes prior to the duplication event. In part this is owing to a negative correlation between coding sequence length and rate of evolution, coupled with a bias toward smaller genes being more duplicable. The effect is masked by difference in expression rate between duplicable genes and singletons. Additionally, in contradiction to the classical assumption, we find no convincing evidence for an increase in dN/dS after duplication, nor for rate asymmetry between duplicates. We conclude that high rates of evolution of duplicated genes are not solely a consequence of the duplication event, but are rather a predictor of duplicability. These results are consistent with a model in which successful gene duplication events in mammals are skewed toward events of minimal phenotypic impact.
P2.01-072 Local Management of Oligometastases in Non-Small Cell Lung Cancer (NSCLC)
Authors: M. Riudavets Melia, L. Del Carpio Huerta, A. Barba Joaquín, G. Anguera Palacios, I. Sullivan, A. Callejo Perez, N. Farré, A. Torrego, V. Pajares, E. Martínez, J.C. Trujillo, C. De Quinana, M. Majem Tarruella
Journal: Journal of Thoracic Oncology (2017)
UK’s first emergency department for patients over 80 to open in Norwich
Authors: Zosia Kmietowicz
Journal: BMJ (2017)

The UK’s first emergency department that is dedicated to patients over the age of 80 will open at Norfolk and Norwich University Hospital (NNUH) at the end of November.

When they arrive at the hospital’s emergency department, patients over 80 will be directed to the Older People’s Assessment Service, which will be staffed by emergency consultants, consultant geriatricians, and emergency and older people’s medicine nurses. GPs will …
TMOD-15. TOCA 511 &amp; TOCA FC: PRE-CLINICAL PROOF OF CONCEPT IN CNS METASTATIC BREAST CANCER
Authors: Akihito Inagaki, Angela M Richardson, Sara A Collins, Kei Hiraoka, Shuichi Kamijima, Jolene Shorr, Harry Gruber, Douglas Jolly, Jaime Merchan, Joyce M Slingerland, Noriyuki Kasahara
Journal: Neuro-Oncology (2017)

Toca 511, a clinical-stage retroviral replicating vector (RRV) encoding an optimized yeast cytosine deaminase (CD) prodrug activator gene, in combination with Toca FC (extended-release 5-fluorocytosine (5-FC)), is designed to produce 5-FU which kills cancer cells and immune-suppressive myeloid cells in the tumor microenvironment, leading to anti-cancer immune activation and long term survival. The combination treatment is currently under evaluation in an international Phase 2/3 trial in patients with recurrent high-grade glioma. In the present study, we investigated the feasibility of further applying Toca 511 to brain-metastatic breast cancer, which frequently arises from highly aggressive, treatment-refractory, “triple-negative” (ER(-) PR(-) HER2(-)) disease, and is associated with a dismal prognosis of 4-6 months survival. We first evaluated in vitro replication kinetics of RRV encoding the GFP reporter gene in MDA-MB-231-BR (human) and JC (murine) breast cancer cells. After virus inoculation at either M.O.I. of 0.01 or 0.1, high levels of transduction were achieved within 1-2 weeks as measured by flow cytometric quantitation of GFP fluorescence. Next, we tested in vitro cytotoxicity by MTS assay after 5-FC treatment of MDA-MB-231BR and JC cells transduced with Toca 511. In both Toca 511-transduced breast cancer lines, cell viability was reduced by approximately 70-85% after exposure to 0.1 mM 5-FC and complete cell killing was observed with 1 mM 5-FC within 4-6 days. In survival studies, animals treated with Toca 511 followed by 5-FC prodrug showed statistically significant (231-BR: p<0.0001, JC: p=0.0003) survival benefit compared to the control group. These data provide preclinical validation for a new Phase Ib trial evaluating RRV-mediated immunotherapy in various types of metastatic malignancies, including CNS-metastatic breast cancer (TOCA 6 trial: clinicaltrials.gov NCT02576665), currently recruiting at the University of Miami.
Grippe aviaire et pandémie grippale – Cinq questions pour 2006
Authors: A Nicoll
Journal: Eurosurveillance (2005)

En janvier de cette annee, en observant que 2005 serait l’annee du Coq dans le calendrier chinois, on pouvait craindre un mauvais presage pour la grippe du poulet (ou aviaire) et la pandemie de grippe. Il est certain que la grippe est l’infection qui a defraye la chronique dans la presse populaire en 2005, et ainsi d’une certaine facon, c’etait une « bonne » annee pour la grippe et ceux qui l’etudient. Cette maladie a capte l’attention qu’elle merite en termes de menace pour l’homme.
P3.01-072 Dacomitinib Versus Gefitinib for First-Line Treatment of Advanced EGFR+ NSCLC in Japanese Patients (ARCHER 1050)
Authors: K. Nakagawa, F. Ohyanagi, T. Kato, T. Takahashi, H. Kaneda, N. Nogami, S. Niho, N. Yamamoto, Y. Fujita, H. Zhang, E. Sbar, T. Wang, R. Linke, F. Tsuji, T. Mok
Journal: Journal of Thoracic Oncology (2017)
QLIF-26. SLEEP DISTURBANCE AMONG ADULT PATIENTS WITH PRIMARY AND SECONDARY BRAIN TUMORS AND THEIR CAREGIVERS: A CROSS-SECTIONAL STUDY
Authors: Megan Jeon, Haryana Dhillon, Eng-Siew Koh, Anna Nowak, Lawrence Lam, Lisa Miller, Nathaniel Marshall, Meera Agar
Journal: Neuro-Oncology (2017)

Emerging evidence suggests a close link between sleep disturbance and clinical outcomes and the health-related quality of life in cancer patients. Yet, understanding sleep disturbance is neglected areas in both neuro-oncology care and research. This study aimed to determine the prevalence and predictors of sleep disturbance in brain tumor patients and caregivers, and explore any interaction between the patient-caregiver dyad’s sleep. Fifty-six adult patients with primary malignant (86.5%) or metastatic (13.5%) brain tumors and their family caregivers (N=31) completed a series of self-report questionnaires in an ambulatory neuro-oncology clinic setting in Australia. Sleep patterns and disturbance were assessed with the Pittsburgh Sleep Quality Index and the Insomnia Severity Index. Of patients, 59.6% reported having poor sleep quality and 17.1% having clinical insomnia. Female patients had longer sleep latency (r=0.34, p=0.014), and use of anti-emetic was associated with poorer sleep quality (r=0.33, p=0.022). Multiple linear regression analysis revealed that while pain, depression, fatigue, and hemiparesis symptom accounted for 42% of the variability in sleep quality, hemiparesis symptom was the only significant predictor of poor sleep quality (p=0.001). Insomnia scores were predicted by disrupting sleep environment, depression, and fatigue (p<0.05), but no other clinical variables, such as current treatment or corticosteroid use. Of caregivers, the prevalence of poor sleep quality and clinical insomnia were 60.0% and 16.1%, respectively. Clinical anxiety was reported by 25.8% of caregivers. Anxiety and pain were significant predictors of sleep quality and insomnia in caregivers (p<0.05). Sleep patterns and scores of the patient-caregiver dyad were not associated. A substantially high prevalence of sleep disturbance and clinical insomnia was found in patients and family caregivers. Demographic and clinical variables had limited influence, indicating that sleep disturbance is a more complex problem than toxicity in this sample. Understanding underlying mechanisms of co-morbid symptoms and options for managements is still warranted.
BCG en Finlande : évolution d’une politique de vaccination universelle vers une politique ciblée
Authors: E Pi Salo
Journal: Eurosurveillance (2006)

En Finlande, la vaccination par le BCG est actuellement proposee a tous les nouveaux-nes, et la couverture vaccinale est superieure a 98%. L’incidence annuelle de la tuberculose est faible, de l’ordre de 6,6/100 000 en 2004 et elle est en baisse constante ces dernieres annees. En Finlande, a la difference des autres pays nordiques, la majorite des cas sont detectes chez des personnes de 65 ans et plus natives de Finlande, et une plus faible proportion (12% des cas) dans la population immigree. Alors que l’incidence elevee de la TB et de la tuberculose multi-resistante dans les pays voisins est preoccupante, aucune augmentation du nombre des cas de TB n’a ete detectee dans la population native de Finlande. La decision a donc ete prise de remplacer la politique de vaccination universelle du BCG par une vaccination ciblee sur les groupes a risque.
Network sui patogeni emergenti di origine alimentare in Germania
Authors: D Werber, A Ammon
Journal: Eurosurveillance (2000)

In Germania si sta creando un network di epidemiologi, microbiologi, veterinari e clinici come supporto alle autorita sanitarie locali e nazionali e a quelle veterinarie nella ricerca epidemiologica di patogeni emergenti di origine alimentare. Questo articolo descrive i metodi usati attualmente per studiare l'Escherichia coli enteroemorragico (EHEC) e la sindrome emolitico-uremica (SEU).
RTHP-04. DOSIMETRIC IMPACTS FROM A TUMOR TREATING FIELDS (TTFIELDS) DEVICE FOR GLIOBLASTOMA MULTIFORME (GBM) PATIENTS UNDERGOING SIMULTANEOUS RADIATION THERAPY
Authors: Taoran Li, Gaurav Shukla, Cheng Peng, Virginia Lockamy, Haisong Liu, Wenyin Shi
Journal: Neuro-Oncology (2017)

Recently an approach to treat Glioblastoma has been the introduced using tumor treating fields (TTFields), in which alternating electric fields are applied via transducer arrays to a patient’s scalp. This technique has been demonstrated improved overall survival from 16mo to 20.9mo. Significant interest has been generated in the use of TTFields during the course of post-operative concurrent chemoradiation to further enhance the effect. However the high density electrodes on the scalp can impact the dosimetry of radiation treatment, which was quantified in this study via physical measurements. The impact from TTFields electrodes was quantified in two ways: surface dose and deep dose. The surface dose underneath TTFields electrodes were measured using a parallel plate ionization chamber at effective 1mm depth, and compared to measurements without electrodes. Comparisons were done for incident beam angles at 5, 15, 30, 60, and 90 degrees relative to the surface. Deep dose measurements were conducted using Scandidos Delta4 diode array. Plans of 5 GBM patients previously treated with VMAT were delivered to Delta4 with and without the TTFields electrodes attached the surface of the device; and measured doses on two orthogonal diode arrays were compared. TTFields electrodes introduced additional buildup effect that increased surface dose directly underneath. This buildup effect increased surface dose by 30% to 110% when beams angled from 5 to 90 degrees relative to the surface. Deep dose measurement by diode array showed dose decrease of 1-2% in most areas shadowed by the electrodes (max decrease 2.54%). The wearing of TTFields electrode during radiation could cause skin dose to increase between 30% and 110% compared to no electrodes. Impact on deep dose during VMAT treatment due to attenuation is in general small (1-2%) but detectable. These dosimetric impacts should be taken into consideration during radiation therapy treatment planning.
RTHP-27. RE-IRRADIATION FOR RECURRENT HIGH GRADE GLIOMA (HGG): EVALUATION OF TOLERABLE RADIATION DOSE AND ROLE OF CHEMOTHERAPY
Authors: Megan Kummerlowe, Colette Shen, Kristin Redmond, Juan Carlos Martinez, Syed Muhammad Usama, Roy E Strowd, Lawrence Kleinberg
Journal: Neuro-Oncology (2017)

Re-irradiation for recurrent HGG remains controversial, although several studies have now suggested a dose of 36 Gy as standard for re-treatment. We retrospectively evaluated outcomes and toxicity following re-irradiation for recurrent HGG, in many cases to higher than 36 Gy. Ninety-six patients, median KPS 80 [range 40-100]), were retreated at a median of 29 months following initial radiation (4.8-203.3 months). The median re-irradiation dose was 41.4 Gy (12.6-54 Gy) to a median lesion volume of 185.5 cm3 (20-901 cm3). Of evaluable treatment plans, the median cumulative (initial- and re-irradiation combined) maximum brainstem dose was 76.6 Gy (6.2-103.4 Gy) and to the optic apparatus 54.9 Gy (5.5-90.9 Gy). Concurrent temozolomide (TMZ) alone was given with 55% of re-irradiation treatments, bevacizumab (BEV) alone with 14%, TMZ+BEV with 12%, and no chemotherapy with 20%. Planned re-irradiation was completed by 90% of patients and was not affected by concurrent chemotherapy. Median overall survival (OS) from primary diagnosis was 108, 73, and 33 months for patients with initial grade I-II, grade III, and grade IV gliomas, respectively (p<0.0001). Better OS from the end of re-irradiation was seen with KPS≥80 (median 10.0 vs. 3.7 months, p<0.0001), initial lower grade disease (14.1 vs. 10.9 vs. 6.2 months for grades II, III, and IV, respectively, p=0.001), and concurrent treatment with TMZ alone (10.7 months vs. 6.7 months for BEV alone, 3.8 months for TMZ+BEV, and 4.5 months for no chemotherapy, p=0.02). Radiation necrosis and grade ≥3 late CNS toxicity were both minimal (<3%) in this group. No brainstem or optic nerve/chiasm injury was identified. Re-irradiation even at doses >36 Gy were safe, well tolerated, and completed in the majority of patients with recurrent HGG. More study is needed to define the optimal re-irradiation dose, the maximal safe dose to critical structures, the role of systemic therapy, and efficacy.
Efficacy of ceritinib administered to patients with crizotinib-refractory, ALK-positive, advanced NSCLC within the Italian compassionate use program
Authors: G. Metro, A. Passaro, G. Lo Russo, L. Bonanno, R. Giusti, V. Gregorc, E. Capelletto, O. Martelli, F.L. Cecere, D. Giannarelli, A. Luciani, A. Bearz, A. Tuzi, V. Scotti, G. Tonini, D. Galetta, A. Carta, H. Soto Parra, A. Morabito, R. Chiari
Journal: Annals of Oncology (2017)
Salmonella enteritidis en Europa occidental, 1995-98: informe de vigilancia procedente de Enter-net
Authors: I. S.T. Fisher
Journal: Eurosurveillance (1999)

Un descenso en la incidencia de infecciones por Salmonella enteritidis fue detectado entre 1993 y 1995, a traves de la base de datos de salmonella de la red Salm-Net (antecesora de Enter-net). En ese periodo, el numero de aislamientos de S. enteritidis cayo de 37.647 a 31.482 (1). Esta reduccion del 16% fue notificada por los siete laboratorios nacionales de referencia que enviaron informacion. Sin embargo, a mediados de 1997 se observo que las notificaciones de este serotipo empezaron a aumentar rapidamente (2). Los datos hoy disponibles, proporcionados por 12 paises para el periodo 1995-1998, reflejan que, en la actualidad, este resurgimiento ha disminuido (figura).
Dos agrupaciones de casos humanos de gripe A/H5N1 en la República de Azerbaiyán, Febrero-Marzo 2006
Authors: A Gilsdorf, N Boxall, V Gasimov, I Agayev, F Mammadzade, P Ursu, E Gasimov, C Brown, S Mardel, D Jankovic, G Pimentel, I Amir Ayoub, E Maher Labib Elassal, C Salvi, D Legros, C Pessoa da Silva, A Hay, R Andraghetti, G Rodier, B Ganter
Journal: Eurosurveillance (2006)

Tras la deteccion del virus gripal A/H5 en aves domesticas y silvestres en Azerbaiyan en Febrero de 2006, se detectaron y declararon a la oficina regional Europea de la OMS (Organizacion Mundial de la Salud) dos clusters de casos posibles de gripe aviar humana debidos a A/H5N1 en las dos primeras semanas de Marzo. El 15 de Marzo de 2006, la OMS formo un equipo internacional, incluyendo expertos en control de infecciones, manejo clinico, epidemiologia, microbiologia y comunicacion, para ayudar el ministerio de Sanidad en sus investigaciones y acciones de respuesta. 
Tras una vigilancia activa, 22 personas – de las cuales fallecieron 6 – se investigaron para la gripe aviar en 6 distritos. La investigacion mostro 8 casos de infeccion por el virus A/H5N1 confirmados por el Centro colaborador de la OMS de la gripe, y un caso probable para el cual no se disponia de ninguna muestra. Dichos casos provenian de dos clusters no relacionados identificados en los distritos de Salyan (7 casos confirmados, de los cuales fallecieron 4), y de Tarter (un caso confirmado y uno probable, ambos mortales). El contacto estrecho con y el hecho de desplumar cisnes infectados se consideraron como la fuente mas probable de exposicion al virus A/H5N1 para el cluster de Salyan, pese a las dificultades para recoger informaciones durante la investigacion, porque las actividades asociadas a la exposicion son ilegales (caza y venta de animales silvestres y de productos derivados). Esos casos son el primer brote a nivel mundial en que las aves silvestres son la fuente mas probable de infecciones humanas por el virus A/H5N1. 
Las actividades de control estuvieron reforzadas mediante el empleo de un laboratorio de campo donde era posible detectar el virus A/H5 en tiempo real por RT/PCR. La vigilancia diaria en la poblacion que se inicio en los dos distritos afectados hace poco probable que aparezcan nuevos casos humanos de gripe aviar no detectados.